Hepatic manifestations in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multi-organic autoimmune disease with a wide variety of clinical manifestations. However, hepatic dysfunction is not included in the diagnostic criteria for the disease and has not been recognized properly. The spectrum of hepatic involvement described in thes...
Gespeichert in:
| Veröffentlicht in: | Lupus 2020-07, Vol.29 (8), p.813-824 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 824 |
|---|---|
| container_issue | 8 |
| container_start_page | 813 |
| container_title | Lupus |
| container_volume | 29 |
| creator | González-Regueiro, José A Cruz-Contreras, Mariana Merayo-Chalico, Javier Barrera-Vargas, Ana Ruiz-Margáin, Astrid Campos-Murguía, Alejandro Espin-Nasser, May Martínez-Benítez, Braulio Méndez-Cano, Victor H Macías-Rodríguez, Ricardo U |
| description | Systemic lupus erythematosus (SLE) is a multi-organic autoimmune disease with a wide variety of clinical manifestations. However, hepatic dysfunction is not included in the diagnostic criteria for the disease and has not been recognized properly. The spectrum of hepatic involvement described in these patients ranges from abnormalities in liver function tests (LFTs) to fulminant hepatic failure. Usually, abnormalities in LFTs are only mild and transient, have a hepatocellular pattern and are not related to SLE but rather are mostly drug related. The most frequent finding on liver biopsy is steatosis (non-alcoholic fatty liver disease). Patients do not frequently progress to advanced chronic liver disease, and their outcome is favourable. Those who develop cirrhosis have traditional risk factors, such as other non-SLE-related conditions. In this work, we aim to review hepatic manifestations in patients with SLE, as well as the diagnostic and therapeutic approaches used for different liver diseases in these patients. |
| doi_str_mv | 10.1177/0961203320923398 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2401118527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203320923398</sage_id><sourcerecordid>2401118527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-816f8c8dc89ffee01dbf7c4fa0c8323766138a6a3a074a0d14df71fd1f64a58a3</originalsourceid><addsrcrecordid>eNp1kM1LAzEQxYMotlbvnmTBi5fVmSRNskcpaoWCFz0vaTbRLfvlzu6h_70p9QMKnobM-83L4zF2iXCLqPUdZAo5CMEh40Jk5ohNUWqdxj0_ZtOdnO70CTsj2gCAwEydsongIgOZqSlTS9_ZoXRJbZsyeBrio20oKZuEtjT4OkrV2I2U-H47fPjaDi2NdM5Ogq3IX3zPGXt7fHhdLNPVy9Pz4n6VOqHmQ2pQBeNM4UwWgveAxTpoJ4MFZ2IGrRQKY5UVFrS0UKAsgsZQYFDSzo0VM3az9-369nOM8fK6JOeryja-HSnnEhDRzLmO6PUBumnHvonpIsWlkkZzHinYU65viXof8q4va9tvc4R812l-2Gk8ufo2Hte1L34PfkqMQLoHyL77v1__NfwCWp59dg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424648722</pqid></control><display><type>article</type><title>Hepatic manifestations in systemic lupus erythematosus</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>González-Regueiro, José A ; Cruz-Contreras, Mariana ; Merayo-Chalico, Javier ; Barrera-Vargas, Ana ; Ruiz-Margáin, Astrid ; Campos-Murguía, Alejandro ; Espin-Nasser, May ; Martínez-Benítez, Braulio ; Méndez-Cano, Victor H ; Macías-Rodríguez, Ricardo U</creator><creatorcontrib>González-Regueiro, José A ; Cruz-Contreras, Mariana ; Merayo-Chalico, Javier ; Barrera-Vargas, Ana ; Ruiz-Margáin, Astrid ; Campos-Murguía, Alejandro ; Espin-Nasser, May ; Martínez-Benítez, Braulio ; Méndez-Cano, Victor H ; Macías-Rodríguez, Ricardo U</creatorcontrib><description>Systemic lupus erythematosus (SLE) is a multi-organic autoimmune disease with a wide variety of clinical manifestations. However, hepatic dysfunction is not included in the diagnostic criteria for the disease and has not been recognized properly. The spectrum of hepatic involvement described in these patients ranges from abnormalities in liver function tests (LFTs) to fulminant hepatic failure. Usually, abnormalities in LFTs are only mild and transient, have a hepatocellular pattern and are not related to SLE but rather are mostly drug related. The most frequent finding on liver biopsy is steatosis (non-alcoholic fatty liver disease). Patients do not frequently progress to advanced chronic liver disease, and their outcome is favourable. Those who develop cirrhosis have traditional risk factors, such as other non-SLE-related conditions. In this work, we aim to review hepatic manifestations in patients with SLE, as well as the diagnostic and therapeutic approaches used for different liver diseases in these patients.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203320923398</identifier><identifier>PMID: 32390496</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Autoimmune diseases ; Biopsy ; Cirrhosis ; Fatty liver ; Humans ; Liver - pathology ; Liver cirrhosis ; Liver diseases ; Liver Diseases - complications ; Liver Diseases - etiology ; Liver Diseases - therapy ; Liver Function Tests ; Lupus ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - physiopathology ; Risk factors ; Steatosis ; Systemic lupus erythematosus</subject><ispartof>Lupus, 2020-07, Vol.29 (8), p.813-824</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-816f8c8dc89ffee01dbf7c4fa0c8323766138a6a3a074a0d14df71fd1f64a58a3</citedby><cites>FETCH-LOGICAL-c365t-816f8c8dc89ffee01dbf7c4fa0c8323766138a6a3a074a0d14df71fd1f64a58a3</cites><orcidid>0000-0002-7637-4477 ; 0000-0001-5211-4710 ; 0000-0002-5870-0523</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203320923398$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203320923398$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,780,784,792,21817,27920,27922,27923,43619,43620</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32390496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González-Regueiro, José A</creatorcontrib><creatorcontrib>Cruz-Contreras, Mariana</creatorcontrib><creatorcontrib>Merayo-Chalico, Javier</creatorcontrib><creatorcontrib>Barrera-Vargas, Ana</creatorcontrib><creatorcontrib>Ruiz-Margáin, Astrid</creatorcontrib><creatorcontrib>Campos-Murguía, Alejandro</creatorcontrib><creatorcontrib>Espin-Nasser, May</creatorcontrib><creatorcontrib>Martínez-Benítez, Braulio</creatorcontrib><creatorcontrib>Méndez-Cano, Victor H</creatorcontrib><creatorcontrib>Macías-Rodríguez, Ricardo U</creatorcontrib><title>Hepatic manifestations in systemic lupus erythematosus</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Systemic lupus erythematosus (SLE) is a multi-organic autoimmune disease with a wide variety of clinical manifestations. However, hepatic dysfunction is not included in the diagnostic criteria for the disease and has not been recognized properly. The spectrum of hepatic involvement described in these patients ranges from abnormalities in liver function tests (LFTs) to fulminant hepatic failure. Usually, abnormalities in LFTs are only mild and transient, have a hepatocellular pattern and are not related to SLE but rather are mostly drug related. The most frequent finding on liver biopsy is steatosis (non-alcoholic fatty liver disease). Patients do not frequently progress to advanced chronic liver disease, and their outcome is favourable. Those who develop cirrhosis have traditional risk factors, such as other non-SLE-related conditions. In this work, we aim to review hepatic manifestations in patients with SLE, as well as the diagnostic and therapeutic approaches used for different liver diseases in these patients.</description><subject>Autoimmune diseases</subject><subject>Biopsy</subject><subject>Cirrhosis</subject><subject>Fatty liver</subject><subject>Humans</subject><subject>Liver - pathology</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Liver Diseases - complications</subject><subject>Liver Diseases - etiology</subject><subject>Liver Diseases - therapy</subject><subject>Liver Function Tests</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - physiopathology</subject><subject>Risk factors</subject><subject>Steatosis</subject><subject>Systemic lupus erythematosus</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1LAzEQxYMotlbvnmTBi5fVmSRNskcpaoWCFz0vaTbRLfvlzu6h_70p9QMKnobM-83L4zF2iXCLqPUdZAo5CMEh40Jk5ohNUWqdxj0_ZtOdnO70CTsj2gCAwEydsongIgOZqSlTS9_ZoXRJbZsyeBrio20oKZuEtjT4OkrV2I2U-H47fPjaDi2NdM5Ogq3IX3zPGXt7fHhdLNPVy9Pz4n6VOqHmQ2pQBeNM4UwWgveAxTpoJ4MFZ2IGrRQKY5UVFrS0UKAsgsZQYFDSzo0VM3az9-369nOM8fK6JOeryja-HSnnEhDRzLmO6PUBumnHvonpIsWlkkZzHinYU65viXof8q4va9tvc4R812l-2Gk8ufo2Hte1L34PfkqMQLoHyL77v1__NfwCWp59dg</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>González-Regueiro, José A</creator><creator>Cruz-Contreras, Mariana</creator><creator>Merayo-Chalico, Javier</creator><creator>Barrera-Vargas, Ana</creator><creator>Ruiz-Margáin, Astrid</creator><creator>Campos-Murguía, Alejandro</creator><creator>Espin-Nasser, May</creator><creator>Martínez-Benítez, Braulio</creator><creator>Méndez-Cano, Victor H</creator><creator>Macías-Rodríguez, Ricardo U</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7637-4477</orcidid><orcidid>https://orcid.org/0000-0001-5211-4710</orcidid><orcidid>https://orcid.org/0000-0002-5870-0523</orcidid></search><sort><creationdate>202007</creationdate><title>Hepatic manifestations in systemic lupus erythematosus</title><author>González-Regueiro, José A ; Cruz-Contreras, Mariana ; Merayo-Chalico, Javier ; Barrera-Vargas, Ana ; Ruiz-Margáin, Astrid ; Campos-Murguía, Alejandro ; Espin-Nasser, May ; Martínez-Benítez, Braulio ; Méndez-Cano, Victor H ; Macías-Rodríguez, Ricardo U</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-816f8c8dc89ffee01dbf7c4fa0c8323766138a6a3a074a0d14df71fd1f64a58a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Autoimmune diseases</topic><topic>Biopsy</topic><topic>Cirrhosis</topic><topic>Fatty liver</topic><topic>Humans</topic><topic>Liver - pathology</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Liver Diseases - complications</topic><topic>Liver Diseases - etiology</topic><topic>Liver Diseases - therapy</topic><topic>Liver Function Tests</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - physiopathology</topic><topic>Risk factors</topic><topic>Steatosis</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González-Regueiro, José A</creatorcontrib><creatorcontrib>Cruz-Contreras, Mariana</creatorcontrib><creatorcontrib>Merayo-Chalico, Javier</creatorcontrib><creatorcontrib>Barrera-Vargas, Ana</creatorcontrib><creatorcontrib>Ruiz-Margáin, Astrid</creatorcontrib><creatorcontrib>Campos-Murguía, Alejandro</creatorcontrib><creatorcontrib>Espin-Nasser, May</creatorcontrib><creatorcontrib>Martínez-Benítez, Braulio</creatorcontrib><creatorcontrib>Méndez-Cano, Victor H</creatorcontrib><creatorcontrib>Macías-Rodríguez, Ricardo U</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González-Regueiro, José A</au><au>Cruz-Contreras, Mariana</au><au>Merayo-Chalico, Javier</au><au>Barrera-Vargas, Ana</au><au>Ruiz-Margáin, Astrid</au><au>Campos-Murguía, Alejandro</au><au>Espin-Nasser, May</au><au>Martínez-Benítez, Braulio</au><au>Méndez-Cano, Victor H</au><au>Macías-Rodríguez, Ricardo U</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatic manifestations in systemic lupus erythematosus</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2020-07</date><risdate>2020</risdate><volume>29</volume><issue>8</issue><spage>813</spage><epage>824</epage><pages>813-824</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Systemic lupus erythematosus (SLE) is a multi-organic autoimmune disease with a wide variety of clinical manifestations. However, hepatic dysfunction is not included in the diagnostic criteria for the disease and has not been recognized properly. The spectrum of hepatic involvement described in these patients ranges from abnormalities in liver function tests (LFTs) to fulminant hepatic failure. Usually, abnormalities in LFTs are only mild and transient, have a hepatocellular pattern and are not related to SLE but rather are mostly drug related. The most frequent finding on liver biopsy is steatosis (non-alcoholic fatty liver disease). Patients do not frequently progress to advanced chronic liver disease, and their outcome is favourable. Those who develop cirrhosis have traditional risk factors, such as other non-SLE-related conditions. In this work, we aim to review hepatic manifestations in patients with SLE, as well as the diagnostic and therapeutic approaches used for different liver diseases in these patients.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32390496</pmid><doi>10.1177/0961203320923398</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-7637-4477</orcidid><orcidid>https://orcid.org/0000-0001-5211-4710</orcidid><orcidid>https://orcid.org/0000-0002-5870-0523</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2020-07, Vol.29 (8), p.813-824 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2401118527 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Autoimmune diseases Biopsy Cirrhosis Fatty liver Humans Liver - pathology Liver cirrhosis Liver diseases Liver Diseases - complications Liver Diseases - etiology Liver Diseases - therapy Liver Function Tests Lupus Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - physiopathology Risk factors Steatosis Systemic lupus erythematosus |
| title | Hepatic manifestations in systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A21%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatic%20manifestations%20in%20systemic%20lupus%20erythematosus&rft.jtitle=Lupus&rft.au=Gonz%C3%A1lez-Regueiro,%20Jos%C3%A9%20A&rft.date=2020-07&rft.volume=29&rft.issue=8&rft.spage=813&rft.epage=824&rft.pages=813-824&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203320923398&rft_dat=%3Cproquest_cross%3E2401118527%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424648722&rft_id=info:pmid/32390496&rft_sage_id=10.1177_0961203320923398&rfr_iscdi=true |